Panacos Pharmaceuticals 8-K 2005
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 30, 2005
V. I. TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
134 Coolidge Avenue
Watertown, Massachusetts 02472
(Address of principal executive offices and zip code)
Registrants telephone number, including area code: (617) 926-1551
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
ITEM 8.01 OTHER EVENTS
On March 30, 2005, V.I. Technologies, Inc. (Vitex or the Company) announced that it has received formal notification from The Nasdaq Stock Market, Inc. (Nasdaq) that the Company has regained compliance with the minimum bid and shareholder equity requirements for continued listing on the Nasdaq National Market. This brings the Company into full compliance with these requirements for continued listing. There are no further actions required of the Company.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.